The content on this site is intended for healthcare professionals only
Dr Jane Meisel comments on the findings from a phase 3 randomised study, known as DESTINY-Breast04, investigating trastuzumab deruxtecan versus treatment of physician’s choice in patients (pts) with HER2-low unresectable and or metastatic breast cancer.
The primary outcome was that DESTINY-Breast 04 is the first phase 3 trial of a HER-2 directed therapy in patients with HER2-low mBC to show a statistically meaningful benefit in PFS and OS compared to the standard of care treatment, regardless of HR status, with a generally manageable safety profile.
Dr Meisel concludes the by discussing the significance of the study findings.
Watch Dr Modi's press conference on the study here
Watch Dr Modi's interview on the study here
Read the news story here
Abemaciclib and fulvestrant show improved efficacy in HR+, HER2- advanced breast cancer compared to placebo and fulvestrant
Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours
Using AI to identify patients at increased risk of side effects from radiation treatment for breast cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
SABCS 2023: Highlights
Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients
Trial investigates multiparametric prognostic score in early HR+/HER2- breast cancer
KEYNOTE-756 trial shows increased response in ER+/HER2- breast cancer
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
